Comparative Pharmacology
Head-to-head clinical analysis: PROPHENE 65 versus VICODIN HP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROPHENE 65 versus VICODIN HP.
PROPHENE 65 vs VICODIN HP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Propoxyphene is a weak opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering perception of pain. It also has local anesthetic and moderate antitussive effects.
Hydrocodone is a mu-opioid receptor agonist that inhibits ascending pain pathways; acetaminophen inhibits cyclooxygenase and has antipyretic effects.
Propoxyphene napsylate 100 mg orally every 4 hours as needed for pain; maximum 600 mg/day.
One tablet (hydrocodone bitartrate 10 mg/acetaminophen 660 mg) orally every 4-6 hours as needed for pain; maximum 6 tablets per day.
None Documented
None Documented
Terminal elimination half-life of propoxyphene: 6-12 hours (mean ~8 hours); norpropoxyphene half-life: 22-36 hours, leading to accumulation with chronic dosing. Clinical context: prolonged half-life in elderly and hepatic impairment increases risk of toxicity.
Hydrocodone: 3.8-5.5 hours (mean 4.5 h). Acetaminophen: 2-3 hours. Clinical context: dosing interval every 4-6 hours for acute pain.
Renal elimination of unchanged drug and metabolites: propoxyphene and its major metabolite norpropoxyphene account for ~20-30% as unchanged drug in urine; remainder as conjugated metabolites. Biliary/fecal elimination accounts for <10%.
Primarily renal: hydrocodone is eliminated as conjugated metabolites (glucuronides) ~80%; unchanged drug ~5%. Biliary/fecal: minor, <10%.
Category C
Category C
Opioid Analgesic
Opioid Analgesic